Effect of Metformin and Probiotics in Reproductive-aged Patients With Polycystic Ovary Syndrome

NCT ID: NCT03336840

Last Updated: 2019-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-01

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to evaluate the safety and effectiveness on the clinical and biological parameters of reproductive-aged PCOS women after a 12-week metformin and/or probiotics administration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Probiotics are live bacteria that offer a health benefit to the host when administered in adequate amounts. Probiotic supplementation is safe for use and has demonstrated beneficial effects for metabolic diseases such as obesity and diabetes. In this study, about 90 reproductive-aged women with PCOS will be enrolled. Participants will be randomly assigned into one of the following three groups: Metformin tablets (0.5g tid po), ProMetS probiotics powder (4g qN po), Metformin tablets (0.5g tid po) and ProMetS probiotics powder (4g qN po), for 12 weeks. Blood and stool samples will be collected before and after treatment. Fasting glucose levels, fasting insulin levels, sex hormone levels, serum lipid profiles, inflammation markers, other metabolic related parameters and change of gut microbiota and immune cells will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

Group Type EXPERIMENTAL

Metformin tablets

Intervention Type DRUG

0.5g (1 pill) of Metformin tablets administered three times a day orally before meal

Probiotics

Group Type EXPERIMENTAL

ProMetS probiotics powder

Intervention Type DRUG

4g (2 strips) of ProMetS probiotics powder administered orally every night

Metformin and Probiotics

Group Type EXPERIMENTAL

1. Metformin tablets; 2. ProMetS probiotics powder

Intervention Type DRUG

1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;
2. 4g (2 strips) of ProMetS probiotics powder administered orally every night

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin tablets

0.5g (1 pill) of Metformin tablets administered three times a day orally before meal

Intervention Type DRUG

ProMetS probiotics powder

4g (2 strips) of ProMetS probiotics powder administered orally every night

Intervention Type DRUG

1. Metformin tablets; 2. ProMetS probiotics powder

1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;
2. 4g (2 strips) of ProMetS probiotics powder administered orally every night

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Premenopausal between 18-40 years of age.
2. Diagnosed PCOS defined as 2003 Rotterdam diagnostic criteria.

Exclusion Criteria

1. During the pregnancy and lactation period.
2. Significant impaired liver function, impaired renal function, mental disease, severe infection, severe anemia, severe heart disease and neutropenia disease.
3. Use of antibiotics within 3 months.
4. Symptoms of any infection at screening.
5. Immunodeficient or use of immunosuppressive drugs.
6. Use of products containing prebiotics or probiotics within the last 3 months.
7. Previous history of gastrointestinal surgery or disease (such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease or other gastrointestinal disorder).
8. Medical conditions or diseases that may affect subject safety or confound study results in the opinion of the investigator
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dalong Zhu

Chief Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dalong Zhu, MD, PhD

Role: CONTACT

86-25-83-105302

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dalong Zhu, MD,PhD

Role: primary

86-25-83-105302

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PCOS2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotic Intervention in PCOS
NCT04593459 COMPLETED PHASE4
Optimizing Metformin Use in Polycystic Ovary Syndrome
NCT07120815 NOT_YET_RECRUITING PHASE3
Comparison of Myoinositol and Metformin in PCO
NCT04204044 UNKNOWN EARLY_PHASE1
Chiglitazar/Metformin in Non-obese Women With PCOS
NCT06125587 COMPLETED PHASE2/PHASE3